UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases
Status:
Recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
This study is a single-arm, multicenter, open-labeled clinical study of UTD1 combined with
Capecitabine in metastatic HER2-negative breast cancaner patients with brain metastases. This
study aims to evaluate the efficacy and safety of UDT1 combined with capecitabine in
metastatic HER2-negative breast cancer patients with brain metastases.